Summary. Exocrine pancreatic function was evaluated by a Lundh meal test and a secretin-cholecystokinin test in 16 patients with chronic pancreatitis. B cell function was assessed by measuring the concentration of C-peptide after stimulation with oral glucose and intravenous glucagon. The C-peptide response to intravenous glucagon and oral glucose was closely correlated (r= 0.88, p < 0.01). Plasma C-peptide after glucagon was significantly correlated to the post-prandial concentration of lipase (r = 0.72, p < 0.001), amylase (r = 0.64, p < 0.05) and to amylase output (r = 0.64, p < 0.05). Eight out of nine patients treated with insulin had residual B cell function, but it diminished significantly with increasing duration of diabetes. We conclude that B cell function is correlated to pancreatic enzyme secretion and that patients with insulintreated diabetes secondary to chronic pancreatitis have a residual insulin secretion similar to that of patients with Type 1 (insulin-dependent) diabetes.
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Attempts to correlate insulin secretion to exocrine pancreatic secretion in patients with chronic pancreatitis have revealed conflicting results (1) (2) (3) (4) (5) . Serum insulin, however, might not be an ideal indicator of B cell function in chronic pancreatitis. This disease is commonly found together with alcoholism and cirrhosis of the liver [6] which is associated with hyperinsulinaemia due to a reduced hepatic extraction of insulin [7, 81 . Unlike insulin, C-peptide is not significantly extracted in the liver [8, 9] , which makes estimation of peripheral C-peptide especially suited as a measurement of B cell function in chronic alcoholism.
The aim of the present study was to investigate a possible connection between exocrine secretion and endocrine function as measured by plasma C-peptide in patients with chronic pancreatitis. Furthermore, we studied the residual B cell function in patients with insulin-dependent diabetes mellitus secondary to chronic pancreatitis.
Material and Methods

Patients
Sixteen patients with chronic pancreatitis were studied after informed consent. The diagnostic criteria were according to the Marseflle classification [10] . No patient had previously been operated upon in the region of the stomach or pancreas and no one had a family history of diabetes. All had a normal renal function judged from serum creatinine. Clinical data are given in Table 1 .
Investigations
All patients underwent the following investigations: (1) A Lundh meal test [11] (5) Patients without overt diabetes (fasting blood glucose > 7.0 mmol/t) had an oral glucose tolerance test with a load of 1.75 g glucose/kg ideal body weight. Venous blood was sampled before and at 30 min intervals during the test and the concentrations of glucose and C-peptide in plasma were measured. (6) Glucagon-Cpeptide test: after an overnight fast an IV bolus injection of 1 mg glucagon (Novo, Copenhagen, Denmark) was given, and blood sampled at -15, 0, 2, 4, 6, 8, 10, 15 and 20 min [12] . Plasma C-peptide was measured in all samples using antiserum M1230 [13] as described by Heding [14] . B cell function was considered present if plasma C-peptide levels were equal to or exceeded 0.06 pmol/ml [12] . Intra-and interassay variations for the assay were 3.2% and 9.6%, respectively [13] .
Statistics
Spearman's rank correlation test, linear regression and the MannWhitney U-test were used. The level of significance was 0.05. Died 9 months after this investigation in an extremely malnurished state, and could be managed without insulin; b Developed insulin-dependent diabetes within one year after the investigation; c Continued to have normal weight and no evidence of diabetes one year after the investigation GTT = glucose tolerance test 
Results
The peak concentration of C-peptide after stimulation with glucagon and oral glucose was closely correlated (r = 0.88, p < 0.01 ; Fig. 1 ). The highest concentration of C-peptide occurred 6 min after the injection of glucagon. Furthermore, the peak and 6-min values were almost identical in individual patients ( Table 2 ). The basal and peak concentration of C-peptide were closely dependent (r = 0.94, p < 0.001 ; Table 2 ).
There was a significant correlation between pancreatic enzyme secretion and the peak concentration of (Tables 2 and 3 ). Patients with steatorrhoea had a significantly lower peak concentration of C-peptide (median value: 0.14 pmol/ml, p < 0.01) than patients without steatorrhoea (median value: 0.55 pmol/ml). B cell function, however, was not significantly lower in patients with pancreatic calcifications compared with patients without (p < 0.1). Eleven patients had diabetes, but there was a certain overlap in the concentration of C-peptide between diabetic and non-diabetic patients ( Table 2 ). The insulin dose was inversely correlated to the glucagon stimulated C-peptide concentration (r = -0.74, p < 0.05). Only one of the nine patients treated with insulin had no detectable B cell function ( Table 2 ). The insulin secretory capacity, as measured by the peak C-peptide concentration after glucagon, diminished with increasing duration of diabetes (r = -0.61, p = 0.05). The same was found when considering only patients on insulin treatment (r = -0.69, p < 0.05).
Discussion
By measuring C-peptide levels, we could conclude that the amount of insulin released by the B cells was significantly correlated to the excretion of pancreatic enzymes, and that this also holds true in patients treated with insulin whohave been excluded from previous studies (2, 4, 5) . This association with exocrine function was also substantiated by the fact that our patients with steatorrhoea had a lower C-peptide secretion than those patients with a lesser degree of exocrine impairment. Such a correlation between C-peptide and exocrine secretion is not limited to patients with chronic pancreatitis, as a similar association has been demonstrated by Frier et al. [151 in Type 1 diabetes.
As in patients without chronic pancreatitis, oral glucose was a more potent stimulus to B cell secretion than intravenous glucagon, but the peak C-peptide concentrations after glucagon and oral glucose were closely correlated, indicating that the glucagon test can be used in patients with chronic pancreatitis.
Our findings indicate that B cell function is similar in diabetes secondary to chronic pancreatitis compared with Type 1 diabetic subjects. The peak concentration of C-peptide occurred at 6 min after glucagon as in Type 1 diabetes [12] and not after 10 min as among normal subjects [12] . Patients with chronic pancreatitis treated with insulin had residual B cell function for the first years after the onset of diabetes, and the residual B cell function declined with increasing duration of diabetes, as in Type 1 diabetic subjects [16] . This suggests that B cell function will finally disappear also in patients with chronic pancreatitis.
Patients with a post-stimulatory concentration of Cpeptide below 0.60 pmol/ml willnormally require insulin [17] . Four of our patients had C-peptide concentrations below that level, but could be managed without insulin. This is an apparent difference between Type 1 diabetes and diabetes secondary to chronic pancreatitis. A low food intake, steatorrhoea and malnutrition might explain why such patients can avoid insulin treatment despite very limited endogenous insulin secretion. The glucagon-C-peptide test might thus be of limited use in predicting whether patients with chronic pancreatitis can be managed without insulin.
In Type 1 diabetes, patients with endogenous insulin secretion have abetter degree of metabolic control and may be better protected against severe ketoacidosis, than patients without B cell function [18, 19] . This has particular relevance to the surgical treatment of patients with chronic pancreatitis. Partial pancreatectomy is likely to worsen B cell function, subtotal pancreatectomy is often associated with diabetes being difficult to control [20] and total pancreatectomy will result in permanent loss of B cell function. Our finding of a preserved B cell function in insulin-treated diabetes secondary to chronic pancreatitis, at least for the first years after the onset of diabetes, suggests that the degree of B cell function should be taken into consideration before surgery of the pancreas.
